Residues of active ingredients from drug production are one of the biggest challenges in modern industrial wastewater treatment. They resist the usual treatment methods and pose a considerable risk to humans and the environment.
A global biotechnology and pharmaceutical company commissioned EnviroChemie to plan, build and commission a wastewater treatment plant for production at a site in south-eastern Europe. Active substances from drug production must be reliably removed from the wastewater so that it can then be discharged safely.
EnviroChemie experts first determined the optimum process combination for removing the active pharmaceutical ingredients (APIs) from the wastewater in their own laboratory. The plant was then designed and built in close consultation with the customer. The wastewater is treated using a process combination of Biomar biological processes, Flomar dissolved air flotation and chemical-physical treatment steps. The system solution has a capacity of 46 m³/h.
The new wastewater treatment plant was put into operation in October 2024. Thanks to the innovative solution installed, the purified water can be safely discharged into the public sewage system.
The company uses our digital service platform WaterExpert™ for system operation. WaterExpert™ records data and supports analysis, guides workflows and provides information for troubleshooting. We also supply the water chemicals and spare parts, provide plant maintenance, undertake mechanical and electrical maintenance and carry out process and MBR checks.
More about the company: https://www.envirochemie.com/en/
[Source: EnviroChemie/News; 9.12.2024]
